fosfomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1243	23155-02-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fosfomycin trometamol fosfomycin fosfomycin tromethamine	An antibiotic produced by Streptomyces fradiae. Molecular weight: 138.06 Formula: C3H7O4P CLOGP: -0.03 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 70.06 ALOGS: -0.47 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fosfomycin trometamol
fosfomycin
fosfomycin tromethamine

An antibiotic produced by Streptomyces fradiae.

Molecular weight: 138.06
Formula: C3H7O4P
CLOGP: -0.03
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 70.06
ALOGS: -0.47
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	O
8	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	82 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	31 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	2 mL/min/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	192.90 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
t_half (Half-life)	1.90 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.32 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 19, 1996	FDA	ZAMBON SPA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	226.80	26.54	51	7323	1856	63479792
Palmoplantar keratoderma	224.20	26.54	51	7323	1956	63479692
Pruritus genital	210.03	26.54	51	7323	2603	63479045
Sleep terror	209.53	26.54	51	7323	2629	63479019
Atrial tachycardia	190.97	26.54	52	7322	4188	63477460
Carotid artery occlusion	181.18	26.54	51	7323	4643	63477005
Tension headache	176.15	26.54	51	7323	5135	63476513
Anosmia	170.45	26.54	53	7321	6807	63474841
Facial pain	148.01	26.54	53	7321	10508	63471140
Immunisation	136.93	26.54	31	7343	1162	63480486

Showing 1 to 10 of 51 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	295.85	54.53	66	6034	1522	34949309
Palmoplantar keratoderma	276.99	54.53	65	6035	1888	34948943
Pruritus genital	264.04	54.53	64	6036	2140	34948691
Sleep terror	260.83	54.53	64	6036	2254	34948577
Tension headache	248.37	54.53	65	6035	2977	34947854
Atrial tachycardia	241.37	54.53	66	6034	3579	34947252
Facial pain	235.69	54.53	65	6035	3639	34947192
Carotid artery occlusion	235.12	54.53	65	6035	3672	34947159
Anosmia	234.91	54.53	66	6034	3958	34946873
Immunisation	201.88	54.53	45	6055	1032	34949799

Showing 1 to 10 of 42 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiospasm	501.39	28.82	114	12461	3187	79728626
Palmoplantar keratoderma	482.68	28.82	113	12462	3603	79728210
Sleep terror	457.14	28.82	112	12463	4346	79727467
Pruritus genital	456.44	28.82	112	12463	4374	79727439
Atrial tachycardia	418.78	28.82	115	12460	7018	79724795
Tension headache	408.31	28.82	113	12462	7098	79724715
Carotid artery occlusion	401.75	28.82	113	12462	7534	79724279
Anosmia	398.75	28.82	116	12459	8728	79723085
Facial pain	356.47	28.82	115	12460	12235	79719578
Pain of skin	325.76	28.82	112	12463	14501	79717312

Showing 1 to 10 of 61 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01XX01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Other antibacterials
ATC	S02AA17	SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:78379	EC 2.5.1.7 inhibitors
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Urinary tract infectious disease	indication	68566005
Escherichia coli urinary tract infection	indication	301011002
Enterococcus Urinary Tract Infection	indication
Kidney disease	contraindication	90708001	DOID:557
Pseudomembranous enterocolitis	contraindication	397683000

Showing 1 to 5 of 5 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.54	acidic
pKa2	5.59	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	Enzyme	MURA_ECOLI	INHIBITOR	IC50	7	CHEMBL	CHEMBL
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1	Enzyme	MURA1_ENTFA				WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2	Enzyme	MURA2_ENTFA				WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	Enzyme	MURA_PSEAE		IC50	4.98	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
FCN	PDB_CHEM_ID
004467	NDDF
004468	NDDF
10813	IUPHAR_LIGAND_ID
108720006	SNOMEDCT_US
108721005	SNOMEDCT_US
142135	RXNORM
29490	MMSL
2N81MY12TE	UNII
3014	INN_ID

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5826	POWDER	3 g	ORAL	ANDA	20 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5826	POWDER	3 g	ORAL	ANDA	20 sections
Fosfomycin Tromethamine	Human Prescription Drug Label	1	50090-6130	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
Fosfomycin Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9470	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
Fosfomycin Tromethamine	Human Prescription Drug Label	1	67877-749	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
Fosfomycin Tromethamine	Human Prescription Drug Label	1	67877-749	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	21 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	69097-579	GRANULE, FOR SOLUTION	3 g	ORAL	ANDA	18 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	70700-268	POWDER	3 g	ORAL	ANDA	20 sections
FOSFOMYCIN TROMETHAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	70700-268	POWDER	3 g	ORAL	ANDA	20 sections
Fosfomycin Tromethamine	HUMAN PRESCRIPTION DRUG LABEL	1	82036-4274	POWDER	3 g	ORAL	NDA authorized generic	22 sections

Showing 1 to 10 of 13 entries

Previous1 2Next